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Background/Aims: Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage 
hepatocellular carcinoma (HCC), but there is much controversy about TACE refractoriness. The aim of this study was to 
identify trends in the actual clinical application of TACE and recognition of TACE refractoriness by Korean experts.
Methods: In total, 17 questionnaires on TACE refractoriness were administered to 161 clinicians via an online survey. 
Multiple answers were allowed for some questions.
Results: Most clinicians agreed that there is a need for standardization of TACE application through  specific scoring 
systems (n=124, 77.0%). TACE refractoriness was predominantly expected by participants when recurrences were 
detected within 1 month (n=70, 43.5%), there were 4 to 6 tumors (n=77, 47.8%), the maximal tumor size was 3–5 cm 
(n=49, 30.4%), and when there was insufficient tumor necrosis despite TACE being repeated more than three times (n=78, 
48.4%). Overall, sorafenib therapy (n=137) and radiotherapy (n=114) were preferred when repeated TACE was considered 
ineffective.
Conclusions: Treatment of HCC is often based on the clinical judgment of clinicians because of the heterogeneity 
among individuals. Experts need to continue discussions on the standardization and sub-classification of HCC treatment 
guidelines in Korea. (Clin Mol Hepatol 2020;26:24-32)
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Study Highlights
This survey focused to investigate the transarterial chemoembolization (TACE) treatment strategy of Korean clinicians for liver cancer. There were 
various opinions and differences of domestic medical staff about TACE refractoriness according to hospital size and location, but most of them 
showed convergence pattern. These results would help to establish the definition of TACE refractoriness and assist in the liver cancer treatment 
strategies in Korea.
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IntroduCtIon
Transarterial chemoembolization (TACE) is being widely used as 
a non-surgical therapy for the simultaneous treatment of chemo-
therapy and selective ischemia for hepatocellular carcinoma (HCC). 
On the basis of a higher level of evidence, TACE has been proven 
to improve the survival rate for patients with intermediate-stage 
HCC, defined as Barcelona-clinic liver cancer (BCLC) stage B HCC, 
for which patients are not candidates for curative strategies such 
as surgical resection, liver transplantation, and local ablative ther-
apies.1-4
Depending on the nature of the tumor, including size, number, 
growth pattern, and anatomical location, the treatment response 
is not always easy to obtain from a single session, showing differ-
ences in outcomes between reports.5,6 Thus, repeated TACEs are 
often performed to achieve a sufficient outcome. However, the 
method for predicting “TACE refractoriness” that does not show 
a therapeutic response even after repeated TACE treatments is 
still unclear. Enhanced criteria of TACE refractoriness were pro-
posed by Japanese experts, which considered insufficient treat-
ment response, increase in tumor number, new structural invasion 
or metastasis, and change in tumor markers.7 In the recent Korean 
guideline,8-10 sorafenib treatment was recommended if the stage 
progressed despite more than three repeated TACE treatments 
within 6 months.
However, in practice, there are too many heterogeneous situa-
tions to select a consistent treatment strategy; therefore, the clini-
cal decision of the primary physician often plays a larger role than 
the formal guidelines in determining the appropriate time to try or 
switch to other therapies including radiotherapy, radiofrequency 
ablation, and sorafenib.
Therefore, we conducted an online survey and summarized the 
results below to identify the trends in the actual clinical applica-
tion of TACE and the recognition of TACE refractoriness among 
the clinicians treating HCC in Korea.
MAtErIALS And MEtHodS
From November 9, 2017 to December 16, 2017, a total of 161 
liver cancer clinicians in Korea were enrolled, including 121 gas-
troenterologists, 15 surgeons, five radiation oncologists, one he-
matologist, and 19 medical doctors of other fields (Table 1). All par-
ticipants were working in tertiary medical centers where treatment 
procedures were performed via an intra-arterial route. Each indi-
vidual accessed the online survey and selected his/her desired an-
swers among the 17 multiple-choice questions. For 11 of the 17 
questions, the participants were allowed to select multiple an-
swers. All participants had worked in their fields for more than 10 
years.
To compare practice patterns according to the size of the hospi-
tal, participants were divided into two groups: the five highest-
volume centers and the lower volume centers. Clinical practice 
patterns according to the location of the hospitals were also com-
pared by dividing participants into two groups: who were located 
in metropolitan areas (Seoul and Gyeonggi provinces) that had 
chance to easily access to the five high-volume centers, and who 
were located in other provinces.
The General Rules for the Clinical and Pathological Study of Pri-
mary liver cancer, developed by the Liver Cancer Study Group of 
Japan, were used to classify portal vein tumor thrombosis.10 Ac-
cording to these rules, the definition of Vp3 was the presence of a 
tumor thrombus in the first branches of the portal vein, and the 
definition of Vp4 was the presence a tumor thrombus in the main 
trunk of the portal vein and/or the contra‐lateral portal vein 
branch to the primarily involved lobe.
Statistical analyses were conducted using the IBM SPSS Statis-
tics software, version 23.0 (IBM Corp., Armonk, NY, USA), and a 
two-sided P-value of <0.05 was considered significant. The Chi-
square test and Fisher’s exact test, as appropriate, were applied 
to compare qualitative variables.
rESuLtS
Baseline information of the participants are summarized in Table 1. 
table 1. Baseline information of the participants (n=161)
Variable Value
Male sex 128 (79.5)
Clinicians working in the high-volume centers 42 (26.1)
Clinicians working in Seoul and Gyeonggi province 120 (74.5)
Specialty
Gastroenterology and hepatology 121 (75.2)
Surgery 15 (9.3)
Radiation oncology 5 (3.1)
Hemato-oncology 1 (0.6)
Others 19 (11.8)
Variables are presented as n (%).
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Of 128 (79.5%) male and 33 (20.5%) female participants, 42 
(26.1%) clinicians were working in the five high-volume centers, 
and 120 (74.5%) clinicians were working in the medical centers 
located in Seoul and Gyeonggi provinces.
Questions about the overall perception of TACE
The survey asked participants the following three yes/no ques-
tions.
Q1. Standardization of TACE application in Korea is necessary 
through specific scoring systems such as the Hepatoma Arterial-
embolization Prognostic score (HAP score) and assessment for re-
treatment with TACE score (ART score).
Q2. The effect of TACE would be different depending on indi-
vidual and tumor characteristics.
Q3. Sub-classification of the intermediate stage is necessary 
where TACE is recommended as a standard therapy.
Most of the clinicians agreed that there are needs for the stan-
dardization of TACE application through specific scoring systems 
(n=124, 77.0%) and the sub-classification of the intermediate 
stage HCC where TACE is recommended as standard therapy 
(n=148, 91.9%). Moreover, most of the respondents (n=157, 
97.5%) expected that the effect of TACE would be different de-
pending on individual and tumor characteristics. There was no 
difference in the answers to the questions depending on the size 
and location of the hospital, except that the clinicians working far 
outside of Seoul more strongly raised the need for scoring systems 
(Fig. 1, Table 2).
Factors affecting TACE treatment response
The survey asked participants the following three questions that 
allowed multiple answers (Fig. 2, Table 3).
Q4. The patient characteristics affecting the response to TACE. 
Many clinicians responded that many variables would affect TACE 
response, especially the tumor size (n=145, 90.1%), number of tu-
mors (n=111, 68.9%), and tumor shape, such as a nodular or infil-
trating type (n=116, 72.0%) (Fig. 2A). Clinicians working in the 
high-volume centers showed a significant tendency to respond 
table 2. Responses to three questions (n=161)
Question Answer No. 
High-volume centers (n=42) Centers in metropolitan (n=120)
Yes No P-value Yes No P-value
Q1 Yes 124 (77.0) 32 (76.2) 92 (77.3) 0.882 86 (71.7) 38 (92.7) 0.005
No 37 (23.0) 10 (23.8) 27 (22.7) 34 (28.3) 3 (7.3)
Q2 Yes 157 (97.5) 40 (95.2) 117 (98.3) 0.279 116 (96.7) 41 (100) 0.573
Not certain 4 (2.5) 2 (4.8) 2 (1.7) 4 (3.3) 0 (0.0)
Q3 Yes 148 (91.9) 39 (92.9) 109 (91.6) 0.962 108 (90.0) 40 (97.6) 0.123
No 2 (1.2) 1 (2.4) 1 (0.8) 2 (1.7) 0 (0.0)
Not certain 11 (6.8) 2 (4.8) 9 (7.6) 10 (8.3) 1 (2.4)
Values are presented as n (%) unless otherwise indicated. ‘Q1’ is ‘standardization of transarterial chemoembolization (TACE) application in Korea is necessary 
through the specific scoring systems such as the Hepatoma Arterial-embolization Prognostic score (HAP score) and, the Assessment for Retreatment with 
TACE score (ART score)’. ‘Q2’ is ‘the effect of TACE would be different depending on individual and tumor characteristics’. ‘Q3’ is ‘sub-classification of the 
intermediate stage is necessary where TACE is recommended as a standard therapy’. P-value was calculated using chi-square test and Fisher’s exact test.
Figure 1. Voting results for three questions for (A) the standardization 
of transarterial chemoembolization (TACE) application, (B) the possibility 
of different TACE effects, and (C) the need for sub-classification for ef-
fective TACE. HAP score, the Hepatoma Arterial-embolization Prognostic 
score; ART score, the Assessment for Retreatment with Transarterial che-
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that the tumor marker (50.0% vs. 27.7%, P=0.013) and tumor 
shape (88.1% vs. 66.4%, P=0.009) were important (Table 3).
Q5. Preferred treatment, based on each clinician’s experience, 
for the patients thought to be poor responders to TACE treatment. 
Sorafenib therapy (n=113, 70.2%) and radiotherapy (n=109, 
67.7%) were predominantly considered when TACE was not ex-
pected to be effective and there were also many responses to 
consider TACE anyway (n=66, 41.0%) or hepatic arterial infusion 
chemotherapy (HAIC) (n=58, 36.0%) (Fig. 2B). Sorafenib was pre-
ferred by clinicians working far outside of Seoul (65.8% vs. 82.9, 
P=0.039) (Table 3).
Q6. The features that cause repeated TACE to be ineffective 
when used in patients with tumors localized in the liver. When 
performing TACE in a patient with a localized HCC in the liver, 
they suggested that TACE was unlikely to be effective in cases 
with a higher number of larger sized of tumors (n=92, 57.1%), re-
current tumors, new lesions within a few months after the previous 
TACE treatment (n=89, 55.3% and n=79, 49.1%, respectively), 
and insufficient lipiodol uptake after TACE (n=77, 47.8%) (Fig. 2C). 
The response to tumor marker elevation (n=46, 28.6%) was sig-
nificantly higher in high-volume centers (40.5% vs 24.4%) (Table 3).
Expectations for TACE refractoriness
There were four questions regarding the situations where TACE 
refractoriness was expected (Fig. 3, Supplementary Table 1).
Q7. How long do you think it would take to detect new lesions 
or recurrences after TACE in TACE refractoriness?
Q8. If new lesions appear after TACE, how many tumors do you 
think are maladaptive for repeated TACE?
Q9. If local recurrences occur after TACE, how large is the maxi-
mal size of a tumor considered for TACE refractoriness?
Q10. How many times should there be insufficient necrosis or 
recurrences after repeated TACE for consideration as TACE refrac-
toriness?
Participants replied as follows; TACE refractoriness was pre-
dominantly expected when new lesions or recurrence were de-
tected at 1 month (n=70, 43.5%), 3 months (n=43, 26.7%), and 
2 months (n=29, 18.0%) after the procedure, respectively. Clini-
cians working in high-volume centers (66.7% vs. 35.3% for 1 
month, P=0.002) or centers near Seoul (50.0% vs. 24.4% for 1 
month, P=0.045) preferred to determine TACE refractoriness at 
an earlier time point (Fig. 3A, Supplementary Table 1). Regarding 
the number of lesions, 4 to 6 lesions (n=77, 47.8%), below 3 le-
sions (n=28, 17.4%), and 7 to 10 lesions (n=21, 13.0%) were fre-
quently selected (Fig. 3B). Regarding the size of the largest lesion, 
3–5 cm (n=49, 30.4%) and 5–7 cm (n=40, 24.8%) were mostly 
chosen (Fig. 3C). Regarding the number of insufficient TACE or re-
peated new lesions, 3 times (n=78, 48.4%) and 2 times (n=62, 
38.5%) were mostly selected (Fig. 3D).
Figure 2. Clinical responses to three questions allowing multiple an-
swers for (A) individual characteristics that affect the response to trans-
arterial chemoembolization (TACE) treatment, (B) subsequent treat-
ments after insufficient TACE, (C) and the possible features that make 
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Preferred treatment strategies after TACE in specific 
situations
Participants replied to the questions that allowed multiple an-
swers about the preferred treatment strategies after TACE in the 
following seven situations; Q11, suspicious TACE failure or refrac-
toriness; Q12, multiple local recurrences with Child-Pugh class A; 
Q13, Vp3/4 portal vein thrombosis; Q14, main portal vein inva-
sion; Q15, extrahepatic metastasis with Child-Pugh class A; Q16, 
extrahepatic metastasis with Child-Pugh class B; Q17, insufficient 
necrosis after at least two treatments of TACE with Child-Pugh 
class A (Fig. 4, Supplementary Table 2).
Overall, sorafenib (n=137, 85.1%), radiotherapy (n=114, 70.8%) 
and HAIC (n=62, 38.5%) were preferred when repeated TACE 
was considered ineffective. Preferred treatment methods in the 
specific conditions after performing TACE were reported as fol-
lows: Repeat TACE (n=111, 68.9%) and sorafenib (n=97, 60.2%) 
for multiple intrahepatic recurrences with Child-Pugh class A. For 
Vp3/4 thrombosis and main portal vein invasion, radiotherapy 
(n=127, 78.9% and n=138, 85.7%, respectively) and sorafenib 
(n=93, 57.8% and n=106, 65.8%, respectively) were preferred. 
Sorafenib (n=153, 95.0%) was preferred for extrahepatic recur-
rence with Child-Pugh class A. In the case of extrahepatic recur-
rence with Child-Pugh class B, hospice care (n=74, 46.0%) was 
preferred with other concurrent therapies (sorafenib [n=65, 
40.4%], radiotherapy [n=61, 37.9%] and other systemic chemo-
therapy [n=51, 31.7%], respectively). When the necrosis of tumors 
with Child-Pugh class A were insufficient after performing more 
than 2 treatments of TACE, radiotherapy (n=113, 70.2%), sorafenib 
(n=94, 58.4%) and repeat TACE (n=75, 46.6%) were preferred 
(Fig. 4). For local control of HCC with advanced stage and Child-
Pugh class A liver function, radiotherapy was preferred over re-
peated trials of TACE treatment in the high-volume centers (Q13, 
P=0.008; Q14, P=0.009; Q17, P=0.011) or centers in the metro-
politan areas (Q14, P=0.032; Q17, P=0.022) (Supplementary Table 2).
table 3. Responses to three questions allowing multiple answers 
Question Answer No.
High-volume centers (n=42)  Centers in metropolitan (n=120)
Yes No P-value  Yes No P-value
Q4 Number of tumor 111 (68.9) 29 (69.0) 82 (68.9) 0.987 81 (67.5) 30 (73.2) 0.498
Size of tumor 145 (90.1) 39 (92.9) 106 (89.1) 0.565 106 (88.3) 39 (95.1) 0.363
Tumor marker 54 (33.5) 21 (50.0) 33 (27.7) 0.013 44 (36.7) 10 (24.4) 0.151
Residual liver function 91 (56.5) 24 (57.1) 67 (56.3) 0.925 71 (59.2) 20 (48.8) 0.247
Tumor shape (nodular or infiltrating) 116 (72.0) 37 (88.1) 79 (66.4) 0.009 91 (75.8) 25 (61.0) 0.067
Q5 Sorafenib 113 (70.2) 32 (76.2) 81 (68.1) 0.322 79 (65.8) 34 (82.9) 0.039
HAIC 58 (36.0) 13 (31.0) 45 (37.8) 0.426 44 (36.7) 14 (34.1) 0.772
Still perform TACE 66 (41.0) 13 (31.0) 53 (44.5) 0.124 52 (43.3) 14 (34.1) 0.302
Beads TACE 22 (13.7) 7 (16.7) 15 (12.6) 0.602 18 (15.0) 4 (9.8) 0.599
Other systemic chemotherapy 16 (9.9) 3 (7.1) 13 (10.9) 0.565 11 (9.2) 5 (12.2) 0.556
Radiotherapy 109 (67.7) 33 (78.6) 76 (63.9) 0.087 83 (69.2) 26 (63.4) 0.497
Q6 Insufficient necrotic area 77 (47.8) 16 (38.1) 61 (51.3) 0.142 61 (50.8) 16 (39.0) 0.191
New lesions within a few months 79 (49.1) 23 (54.8) 56 (47.1) 0.391 53 (44.2) 26 (63.4) 0.033
Local recurrences within a few months 89 (55.3) 22 (52.4) 67 (56.3) 0.660 62 (51.7) 27 (65.9) 0.115
Tumor size or number 92 (57.1) 24 (57.1) 68 (57.1) 1.000 68 (56.7) 24 (58.8) 0.835
Tumor marker elevation 46 (28.6) 17 (40.5) 29 (24.4) 0.047 36 (30.0) 10 (24.4) 0.492
Short interval between repeated TACE 36 (22.4) 10 (23.8) 26 (21.8) 0.793 23 (19.2) 13 (31.7) 0.096
Others 15 (9.3) 6 (14.3) 9 (7.6) 0.221 11 (9.2) 4 (9.8) 1.000
Values are presented as n (%) unless otherwise indicated. ‘Q4’ is ‘the patient characteristics affecting the response to transarterial chemoembolization 
(TACE)’. ‘Q5’ is ‘preferred treatment based on each clinicians’ experience for the cases thought to be poor responders to TACE’. ‘Q6’ is ‘the features that make 
repeated TACE ineffective when performed with tumors localized in the liver.’ P-value was calculated using chi-square test and Fisher’s exact test.
HAIC, hepatic arterial infusion chemotherapy. 
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dISCuSSIon
The effects of TACE on HCC and the changes in survival pat-
terns may vary depending on the patient’s residual liver function 
and the characteristics of the tumor itself, so it is often necessary 
to repeatedly perform TACE because a single trial does not obtain 
sufficient results in many cases.11,12 It is still controversial whether 
treatment should be changed during repeated TACE or whether 
the effect obtained at some time point will help predict a patient’s 
survival.5,13 Although the recent HCC guideline by the Korean Liver 
Cancer Association suggested that progression of the disease af-
ter multiple trials of TACE treatment could be regarded as TACE 
refractoriness,14 there has been no actual definition of TACE re-
fractoriness that can help further establish a treatment plan.
Therefore, the survey was conducted to see how medical staff 
in Korea were actually applying TACE in their work fields. In this 
survey, tumor number, size, and shape (nodular or infiltrative 
type) were considered as factors to affect the response to TACE 
treatment. A short period (about 1–3 months) until the appear-
ance of the new lesions or recurrences, the maximum size of 3–7 
cm of local recurrence, and the insufficient necrosis or recurrences 
after 2–3 times of repeated TACE treatments were considered to 
be suitable for TACE refractoriness. For multiple local recurrence, 
participants responded that repeated TACE treatment could be 
performed. However, for patients with advanced stage or sus-
pected TACE refractoriness, clinicians selected sorafenib and lo-
calized radiotherapy more frequently. Radiotherapy was more pre-
ferred to be performed by the clinicians in the large medical 
centers or centers with good accessibility to the larger centers, 
probably because the high-volume centers had sufficient experi-
ence and appropriate facilities to perform radiation therapy.
TACE is useful because it can minimize impairment of hepatic 
function while improving treatment response and survival rate. 
However, at a certain point in time, repeated TACE treatments 
could show refractory patterns that diminish its usefulness and 
result in necrosis of multifocal lesions, which could lead to aggra-
vation of liver function and worse patient survival.7 Therefore, it is 
important to determine a precise definition of TACE refractoriness 
to maximize the effectiveness of TACE itself and other therapies.
Many efforts have been made to subclassify the intermediate 
stage or provide prediction models through other scoring systems. 
Sub-classification by applying the Milan criteria and up to 7 crite-
ria had been proposed, while classifying HCC patients in the inter-
mediate stage into B1, B2, B3, B4, and Quasi-C groups according 
to basal liver function and the presence of marginal portal throm-
bus.6 The HAP score began as a predictive model for the effec-
tiveness of the first TACE by scoring serum albumin, serum total 
bilirubin, serum alpha-fetoprotein, and maximum tumor size.15 
Moreover, the modified HAP-II scoring system, which additionally 
evaluated the presence of multiple tumors, showed efficacy in 
280 patients with HCC in Korea.16 The ART score system, includ-
ing the Child-Pugh score, serum aspartate aminotransperase, and 
response evaluation after the first TACE,17 has not shown efficacy 
in other studies of HCC patients with chronic hepatitis C in Ja-
pan,18 Italy,19 and France20 and chronic hepatitis B in Taiwan,21 and 
it was also ineffective in evaluating the efficacy of repeated drug-
eluting bead TACE for HCC patients in a Spanish multicenter 
study.22 However, combined application of the ART score after 
classification with the HAP score showed a significant efficacy in 
predicting TACE refractoriness in a recent multicenter study, and 
an algorithm for performing repeat TACE in early- and intermedi-
ate-stage HCC was suggested, and repeated TACE could be per-
formed for patients with an ART score less than 2.5 after the first 
TACE.23
Some recent studies have shown that obtaining a complete re-
Figure 3. Answers to questions about transarterial chemoembolization 
(TACE) refractoriness. (A) Q7, how long do you think it would take to de-
tect new lesions or recurrences after TACE in TACE refractoriness? (B) Q8, 
if new lesions appear after TACE, how many tumors do you think are 
maladaptive for repeated TACE? (C) Q9, if local recurrences occur after 
TACE, how large is the maximal size of tumors considered for TACE re-
fractoriness? (D) Q10, how many times should there be insufficient ne-
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sponse at an earlier time strongly predicted a favorable survival 
outcome in patients with HCC.13,24,25 Moreover, BCLC stage, pre-
treatment alpha-fetoprotein level, and tumor number were also 
independent risk factors for overall survival along these stud-
ies.13,24 Regarding this, not only the on-treatment response but 
also baseline tumor characteristics and laboratory data could be 
used as official predictors for TACE refractoriness in the guideline. 
Assessing TACE refractoriness as quickly as possible could provide 
clinicians with the opportunity to make treatment strategies easier 
(such as localized radiotherapy, TACE, and concurrent therapies) 
and to increase the effectiveness of these next treatment strate-
gies.
According to the results of this survey, the treatment of HCC fa-
vored by participants were not significantly different from the 
treatments recommended in the BCLC stage or proposed by the 
various scoring systems or sub-classifications as mentioned 
above. Of course, the management of HCC is difficult to simply 
standardize and the clinical judgment of the primary care physi-
cian considering individual tumor characteristics, economic situa-
tion, and the familial environment is still important, but is difficult 
without sufficient clinical experience. Therefore, standardization 
of treatments that many physicians can use is still necessary. 
There is also a need for experts to continue to discuss the subdivi-
sion of guidelines for the treatment of HCC in Korea.
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